Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

IPHA

Innate Pharma (IPHA)

Innate Pharma SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPHA
DateTimeSourceHeadlineSymbolCompany
12/09/20246:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
12/09/20241:00AMBusiness WireInnate Pharma présente à l’ASH 2024 des données de l’étude de Phase 2 TELLOMAK sur l’amélioration de la qualité de vie chez des patients atteints de lymphomes T cutanésNASDAQ:IPHAInnate Pharma SA
12/09/20241:00AMBusiness WireInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell LymphomaNASDAQ:IPHAInnate Pharma SA
12/06/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
12/06/20241:00AMBusiness WireInnate Pharma et l’Institut d’Innovation pour le Lymphome Folliculaire (IFLI) annoncent un investissement jusqu’à 7,9 millions de dollars de l’IFLI pour soutenir le développement d’IPH6501 dans le lymphome folliculaireNASDAQ:IPHAInnate Pharma SA
12/06/20241:00AMBusiness WireInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular LymphomaNASDAQ:IPHAInnate Pharma SA
12/03/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
12/03/20241:00AMBusiness WireInnate Pharma partage les présentations sélectionnées pour le congrès annuel de l’ASH 2024NASDAQ:IPHAInnate Pharma SA
12/03/20241:00AMBusiness WireInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024NASDAQ:IPHAInnate Pharma SA
11/20/20246:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
11/20/20241:00AMBusiness WireInnate Pharma Releases Its 2025 Financial CalendarNASDAQ:IPHAInnate Pharma SA
11/20/20241:00AMBusiness WireInnate Pharma publie son calendrier financier pour 2025NASDAQ:IPHAInnate Pharma SA
11/19/20246:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
11/19/20241:00AMBusiness WireInnate Pharma annonce une publication dans la revue Science Immunology mettant en avant le NK cell engager ANKET® de nouvelle génération IPH6501NASDAQ:IPHAInnate Pharma SA
11/19/20241:00AMBusiness WireInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501NASDAQ:IPHAInnate Pharma SA
11/13/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
11/13/20241:00AMBusiness WireInnate Pharma présente ses résultats financiers au troisième trimestre 2024NASDAQ:IPHAInnate Pharma SA
11/13/20241:00AMBusiness WireInnate Pharma Reports Third Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
11/08/20246:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
11/08/20241:00AMBusiness WireInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024NASDAQ:IPHAInnate Pharma SA
11/08/20241:00AMBusiness WireInnate Pharma annonce les présentations de données de son portefeuille innovant en oncologie sélectionnées pour le congrès annuel du SITC 2024NASDAQ:IPHAInnate Pharma SA
11/07/20241:00AMBusiness WireInnate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business UpdatesNASDAQ:IPHAInnate Pharma SA
11/07/20241:00AMBusiness WireInnate Pharma organise une conférence téléphonique pour ses résultats financiers et l’avancée de son portefeuille au troisième trimestre 2024NASDAQ:IPHAInnate Pharma SA
10/29/20242:00AMBusiness WireInnate Pharma annonce sa participation à de prochaines conférences investisseursNASDAQ:IPHAInnate Pharma SA
10/29/20242:00AMBusiness WireInnate Pharma Announces Its Participation in Upcoming Investor ConferencesNASDAQ:IPHAInnate Pharma SA
10/14/20241:00AMBusiness WireInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive BoardNASDAQ:IPHAInnate Pharma SA
10/14/20241:00AMBusiness WireJonathan Dickinson est nommé Président du Directoire d’Innate PharmaNASDAQ:IPHAInnate Pharma SA
09/30/20241:00AMBusiness WireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024NASDAQ:IPHAInnate Pharma SA
09/30/20241:00AMBusiness WireInnate Pharma co-organise un symposium scientifique en présence d’experts de l’Immunotherapie à New York le 3 octobre 2024NASDAQ:IPHAInnate Pharma SA
09/23/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
 Showing the most relevant articles for your search:NASDAQ:IPHA